Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor ...

Most noteworthy is the danger of eating charred or burnt food, which contain toxic compounds that can raise the chances of developing prostate, bowel and ultra-lethal pancreatic cancer.

The approval follows promising late-stage trial results showing that Cabometyx (cabozantinib) is effective in treating adults and children (12+) with previously treated, advanced pancreatic and ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

“The characteristics of NET vary widely from patient to patient, and very few treatment options have demonstrated the ability to improve outcomes across such a heterogeneous population,” said Jennifer ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...